Bottom line
BHCFX vs GGHCX: the short answer
BHCFX (Baron Health Care Fund) and GGHCX (INVESCO Health Care Fund) are both mutual funds.
GGHCX is cheaper at 1.07% vs 1.1% — a difference of $3.00 a year per $10,000 invested.
Over five years, GGHCX returned +2.6% a year vs +2.5% for BHCFX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
BHCFX vs GGHCX side by side
| BHCFX | GGHCX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Baron Select | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.1% | 1.07% |
| Annual cost per $10k | $110 | $107 |
| 10-yr cost on $10k (prospectus) | $1,340 | $1,784 |
| Max front load | — | 5.5% |
| 12b-1 fee | 0.25% | 0.25% |
| 1-yr return | +10.0% | +9.2% |
| 5-yr return (annualized) | +2.5% | +2.6% |
| 10-yr return (annualized) | — | +5.8% |
| Best quarter | +24.6% | +19.6% |
| Worst quarter | −10.0% | −16.5% |
| Net assets (fund) | $114.1M | $1.2B |
| Number of holdings | 43 | 82 |
| Portfolio turnover | 74% | 59% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BHCFX | GGHCX | Difference |
|---|---|---|---|
| 2025 | +10.0% | +15.5% | −5.5% |
| 2024 | +1.3% | +4.0% | −2.7% |
| 2023 | +6.2% | +3.1% | +3.1% |
| 2022 | −17.1% | −13.5% | −3.6% |
| 2021 | +15.5% | +12.2% | +3.3% |
| 2020 | +47.4% | +14.5% | +33.0% |
| 2019 | +35.2% | +32.0% | +3.2% |
Source: Fund prospectus bar charts
Holdings overlap
11 of BHCFX's top 25 holdings also appear in GGHCX's top 25.
| Holding | BHCFX | GGHCX |
|---|---|---|
| Eli Lilly & Co | 13.66% | 10.59% |
| Johnson & Johnson | 5.56% | 6.76% |
| Argenx SE | 4.23% | 3.24% |
| Thermo Fisher Scientific Inc | 3.91% | 1.55% |
| Welltower Inc | 3.38% | 2.34% |
| UnitedHealth Group Inc | 3.28% | 6.17% |
| Edwards Lifesciences Corp | 2.64% | 1.56% |
| Vertex Pharmaceuticals Inc | 2.61% | 2.01% |
| Merck & Co Inc | 2.48% | 4.59% |
| Guardant Health Inc | 2.17% | 2.04% |
| Gilead Sciences Inc | 1.99% | 3.63% |
Source: SEC Form N-PORT
BHCFX top 10
- Eli Lilly & Co — 13.66%
- Mettler-Toledo International Inc — 5.60%
- Johnson & Johnson — 5.56%
- Argenx SE — 4.23%
- Thermo Fisher Scientific Inc — 3.91%
- Roivant Sciences Ltd — 3.88%
- Teva Pharmaceutical Industries Ltd — 3.86%
- Welltower Inc — 3.38%
- UnitedHealth Group Inc — 3.28%
- RadNet Inc — 3.24%
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
FAQ
What is the difference between BHCFX and GGHCX?
Which is cheaper, BHCFX or GGHCX?
Should I own both BHCFX and GGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.